Catherine Longworth is a reporter covering commercial and R&D developments in the medtech industry. A graduate of St. George's, University of London, Catherine holds a BSc in Biomedical Science. Before joining Informa, she worked in the editorial team at Pharmaceutical Press, the publishing division of the Royal Pharmaceutical Society, where she wrote and edited for a number of pharmaceutical publications. After gaining experience in the world of scientific publishing, Catherine took the leap to study a postgraduate qualification in journalism. During the course, she carried out placements with local London newspapers, writing general news and building her portfolio by reporting on a wide range of current affairs such as the European migrant crisis, political protests and the London mayoral election. Catherine is passionate about human rights and is fascinated by the innovative nature of the medtech industry and the healthcare advances that have the greatest benefit to mankind. She lives in London and loves music, arts, travel, writing, reading and is always happy to receive recommendations for books or places to travel!
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Catherine Longworth
Medtech Insight highlights Q3 2018 results from some of the leading IVD players. In this edition, we spotlight some of the big companies including Roche Diagnostics, Thermo Fisher Scientific, bioMérieux, and Becton Dickinson.
Device Week, Nov. 2, 2018 – Third-Quarter Earnings Report Update From IVD, Cardio, and Ortho Companies
On this week's podcast, Reed Miller and Catherine Longworth give an overview of the third-quarter earnings reports from the major public companies in the in vitro diagnostics, cardiovascular and orthopedics device sectors.
The French region of Brittany is emerging as a leading area for the development of biotech derived from marine resources, with nearly 70 enterprises currently active across the region. Key players assembled at the bi-annual SeaTech Week held in Brest to discuss how marine bioresources can inspire a new wave of health-care innovation.
Liver-diagnostics firm Glycotest has secured a $10m investment from Chinese healthcare group Shanghai Fosun Pharmaceutical (Fosun Pharma) to drive commercialization of its HCC Panel test for early-stage liver cancer.